At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Nov 12, 2026 at 16:38 ET
Three insiders at United Therapeutics sold a total of $1.67M in open-market sales within a week of the company reporting Q3 revenue above consensus but EPS below consensus due to a $130M in-process R&D charge. CEO Martine Rothblatt's sales were under a 10b5-1 plan, while director Christopher Patrusky's sale was not. The total value is 0.007% of the $25.1B market cap, well below the 0.1% threshold for materiality.
- Three insiders sold a total of $1.67M in open-market sales over a 7-day window ending Nov 10, 2026.
- CEO Martine Rothblatt sold $288K under a 10b5-1 plan; EVP & General Counsel Paul Mahon sold $683K under a 10b5-1 plan; Director Christopher Patrusky sold $702K without a 10b5-1 plan.
- Total sales represent approximately 0.007% of the $25.1B market cap, which is trivial.
- Q3 2026 revenue of $832.5M beat the $781.1M consensus, but GAAP diluted EPS of $5.71 missed the $6.04 consensus due to a $130M in-process R&D charge from the Thymmune acquisition.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access